Glyconanoparticles as tools to prevent antimicrobial resistance.
Antibacterial infections
Glycans
Saccharide antigens
Vaccine platforms
Journal
Glycoconjugate journal
ISSN: 1573-4986
Titre abrégé: Glycoconj J
Pays: United States
ID NLM: 8603310
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
28
12
2020
accepted:
28
02
2021
revised:
24
02
2021
pubmed:
18
3
2021
medline:
25
2
2022
entrez:
17
3
2021
Statut:
ppublish
Résumé
The increased phenomenon of antimicrobial resistance and the slow pace of development of new antibiotics are at the base of a global health concern regarding microbial infections. Antibiotic resistance kills an estimated 700,000 people each year worldwide, and this number is expected to increase dramatically if efforts are not made to develop new drugs or alternative containment strategies. Increased vaccination coverage, improved sanitation or sustained implementation of infection control measures are among the possible areas of action. Indeed, vaccination is one of the most effective tools of preventing infections. Starting from 1970s polysaccharide-based vaccines against Meningococcus, Pneumococcus and Haemophilus influenzae type b have been licensed, and provided effective protection for population. However, the development of safe and effective vaccines for infectious diseases with broad coverage remains a major challenge in global public health. In this scenario, nanosystems are receiving attention as alternative delivery systems to improve vaccine efficacy and immunogenicity. In this report, we provide an overview of current applications of glyconanomaterials as alternative platforms in the development of new vaccine candidates. In particular, we will focus on nanoparticle platforms, used to induce the activation of the immune system through the multivalent-displacement of saccharide antigens.
Identifiants
pubmed: 33728545
doi: 10.1007/s10719-021-09988-6
pii: 10.1007/s10719-021-09988-6
pmc: PMC7964520
doi:
Substances chimiques
Glycoconjugates
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
475-490Commentaires et corrections
Type : ErratumIn
Références
Bakker-Woudenberg, I.A.J.M.: Delivery of antimicrobials to infected tissue macrophages. Adv. Drug Deliv. Rev. 17(1), 5–20 (1995). https://doi.org/10.1016/0169-409X(95)00037-8
doi: 10.1016/0169-409X(95)00037-8
Hutchings, M.I., Truman, A.W., Wilkinson, B.: Antibiotics: past, present and future. Curr. Opin. Microbiol. 51, 72–80 (2019). https://doi.org/10.1016/j.mib.2019.10.008
doi: 10.1016/j.mib.2019.10.008
pubmed: 31733401
Etebu, E., Arikekpar, I.: Antibiotics : classification and mechanisms of action with emphasis on molecular perspectives. Int. J. Appl. Microbiol. 4, 90–101 (2016)
Kohanski, M.A., Dwyer, D.J., Collins, J.J.: How antibiotics kill bacteria: from targets to networks. Nat. Rev. Microbiol. 8(6), 423–435 (2010). https://doi.org/10.1038/nrmicro2333
doi: 10.1038/nrmicro2333
pubmed: 20440275
pmcid: 2896384
McDermott, P.F., Walker, R.D., White, D.G.: Antimicrobials: modes of action and mechanisms of resistance. Int. J. Toxicol. 22(2), 135–143 (2003). https://doi.org/10.1080/10915810305089
doi: 10.1080/10915810305089
pubmed: 12745995
Kohanski, M.A., Dwyer, D.J., Hayete, B., Lawrence, C.A., Collins, J.J.: A common mechanism of cellular death induced by bactericidal antibiotics. Cell. 130(5), 797–810 (2007). https://doi.org/10.1016/j.cell.2007.06.049
doi: 10.1016/j.cell.2007.06.049
pubmed: 17803904
Ventola, C.L.: The antibiotic resistance crisis: part 1: causes and threats. P & T : a peer-reviewed J. Formul. Manag. 40(4), 277–283 (2015)
Prevention, C.f.D.C.a.: 2019 AR Threats Report. https://www.cdc.gov/drugresistance/biggest-threats.html
WHO: Global antimicrobial resistance and use surveillance system (GLASS) report Early implementation 2020. https://www.who.int/glass/resources/publications/early-implementation-report-2020/en/ (2020)
Greenwood, B.: The contribution of vaccination to global health: past, present and future. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 369(1645), 20130433 (2014). https://doi.org/10.1098/rstb.2013.0433
doi: 10.1098/rstb.2013.0433
Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000–2008. MMWR Morb. Mortal. Wkly Rep. 57(42),1148-1151 (2008)
Tahamtan, A., Charostad, J., Hoseini Shokouh, S.J., Barati, M.: An overview of history, evolution, and manufacturing of various generations of vaccines. J. Arch. Mil. Med. 5(3), e12315 (2017). https://doi.org/10.5812/jamm.12315
doi: 10.5812/jamm.12315
Grabenstein, J.D., Musher, D.M.: 47 - pneumococcal polysaccharide vaccines. In: Plotkin, S.a., Orenstein, W.a., Offit, P.a., Edwards, K.M. (Eds.) Plotkin's Vaccines (Seventh Edition). Pp. 816–840.e813. Elsevier, (2018)
Filloux, A., Whitfield, C.: Editorial: the many wonders of the bacterial cell surface. FEMS Microbiol. Rev. 40(2), 161–163 (2016). https://doi.org/10.1093/femsre/fuv047
doi: 10.1093/femsre/fuv047
pubmed: 26684539
Micoli, F., Costantino, P., Adamo, R.: Potential targets for next generation antimicrobial glycoconjugate vaccines. FEMS Microbiol. Rev. 42(3), 388–423 (2018). https://doi.org/10.1093/femsre/fuy011
doi: 10.1093/femsre/fuy011
pubmed: 29547971
pmcid: 5995208
Makabenta, J.M.V., Nabawy, A., Li, C.H., Schmidt-Malan, S., Patel, R., Rotello, V.M.: Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections. Nat. Rev. Microbiol. 19(1), 23–36 (2021). https://doi.org/10.1038/s41579-020-0420-1
doi: 10.1038/s41579-020-0420-1
pubmed: 32814862
Mahavir, J., Sneh, L., Preeti, K., Tulika, M.: Application of nanostructures in antimicrobial therapy. Int. J. Appl. Pharm. 10(4), 11–25 (2018). https://doi.org/10.22159/ijap.2018v10i4.25803
doi: 10.22159/ijap.2018v10i4.25803
Morelli, L., Cappelluti, M.A., Ricotti, L., Lenardi, C., Gerges, I.: An injectable system for local and sustained release of antimicrobial agents in the periodontal pocket. Macromol. Biosci. 17(8), 1700103 (2017). https://doi.org/10.1002/mabi.201700103
doi: 10.1002/mabi.201700103
Pati, R., Shevtsov, M., Sonawane, A.: Nanoparticle vaccines against infectious diseases. Frontiers in Immunology 9(2224) (2018). doi: https://doi.org/10.3389/fimmu.2018.02224
Reichardt, N.C., Martín-Lomas, M., Penadés, S.: Glyconanotechnology. Chem. Soc. Rev. 42(10), 4358–4376 (2013). https://doi.org/10.1039/C2CS35427F
doi: 10.1039/C2CS35427F
pubmed: 23303404
Marradi, M., Chiodo, F., García, I., Penadés, S.: Glyconanoparticles as multifunctional and multimodal carbohydrate systems. Chem. Soc. Rev. 42(11), 4728–4745 (2013). https://doi.org/10.1039/C2CS35420A
doi: 10.1039/C2CS35420A
pubmed: 23288339
Compostella, F., Pitirollo, O., Silvestri, A., Polito, L.: Glyco-gold nanoparticles: synthesis and applications. Beilstein J. Org. Chem. 13, 1008–1021 (2017). https://doi.org/10.3762/bjoc.13.100
doi: 10.3762/bjoc.13.100
pubmed: 28684980
pmcid: 5480336
Polito, L.: Glyconanoparticles as versatile platforms for vaccine development: A minireview In: Recent Trends in Carbohydrate Chemistry. Elsevier Ed. Vol 2: Synthesis and Biomedical Applications of Glycans and Glycoconjugates, pages 381-411 (2020).
Zhao, P., Li, N., Astruc, D.: State of the art in gold nanoparticle synthesis. Coord. Chem. Rev. 257(3), 638–665 (2013). https://doi.org/10.1016/j.ccr.2012.09.002
doi: 10.1016/j.ccr.2012.09.002
Turkevich, J., Stevenson, P.C., Hillier, J.: A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss. Faraday Soc. 11(0), 55–75 (1951). https://doi.org/10.1039/DF9511100055
doi: 10.1039/DF9511100055
Brust, M., Walker, M., Bethell, D., Schiffrin, D.J., Whyman, R.: Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid–liquid system. Journal of the chemical society. Chem. Commun. (7). 801–802 (1994). https://doi.org/10.1039/C39940000801
Amendola, V., Pilot, R., Frasconi, M., Maragò, O.M., Iatì, M.A.: Surface plasmon resonance in gold nanoparticles: a review. J. Phys. Condens. Matter. 29(20), 203002 (2017). https://doi.org/10.1088/1361-648x/aa60f3
doi: 10.1088/1361-648x/aa60f3
pubmed: 28426435
Kohout, C., Santi, C., Polito, L.: Anisotropic gold nanoparticles in biomedical applications. Int. J. Mol. Sci. 19(11) (2018). doi: https://doi.org/10.3390/ijms19113385
Yang, L., Zhou, Z., Song, J., Chen, X.: Anisotropic nanomaterials for shape-dependent physicochemical and biomedical applications. Chem. Soc. Rev. 48(19), 5140–5176 (2019). https://doi.org/10.1039/C9CS00011A
doi: 10.1039/C9CS00011A
pubmed: 31464313
pmcid: 6768714
Pitirollo, O., Micoli, F., Necchi, F., Mancini, F., Carducci, M., Adamo, R., Evangelisti, C., Morelli, L., Polito, L., Lay, L.: Gold nanoparticles morphology does not affect the multivalent presentation and antibody recognition of group a Streptococcus synthetic oligorhamnans. Bioorg. Chem. 99, 103815 (2020). https://doi.org/10.1016/j.bioorg.2020.103815
doi: 10.1016/j.bioorg.2020.103815
pubmed: 32289587
Pavot, V., Berthet, M., Rességuier, J., Legaz, S., Handké, N., Gilbert, S.C., Paul, S., Verrier, B.: Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery. Nanomedicine. 9(17), 2703–2718 (2014). https://doi.org/10.2217/nnm.14.156
doi: 10.2217/nnm.14.156
pubmed: 25529572
Anish, C., Khan, N., Upadhyay, A.K., Sehgal, D., Panda, A.K.: Delivery of polysaccharides using polymer particles: implications on size-dependent immunogenicity, Opsonophagocytosis, and protective immunity. Mol. Pharm. 11(3), 922–937 (2014). https://doi.org/10.1021/mp400589q
doi: 10.1021/mp400589q
pubmed: 24446810
Meena, J., Kumar, R., Singh, M., Ahmed, A., Panda, A.K.: Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of vi polysaccharide conjugate using PLA nanoparticles. Eur. J. Pharm. Biopharm. 152, 270–281 (2020). https://doi.org/10.1016/j.ejpb.2020.05.023
doi: 10.1016/j.ejpb.2020.05.023
pubmed: 32470636
Goodman, J.T., Vela Ramirez, J.E., Boggiatto, P.M., Roychoudhury, R., Pohl, N.L.B., Wannemuehler, M.J., Narasimhan, B.: Nanoparticle chemistry and functionalization differentially regulates dendritic cell–nanoparticle interactions and triggers dendritic cell maturation. Part. Part. Syst. Charact. 31(12), 1269–1280 (2014). https://doi.org/10.1002/ppsc.201400148
doi: 10.1002/ppsc.201400148
Anish, C., Goswami, D.G., Kanchan, V., Mathew, S., Panda, A.K.: The immunogenic characteristics associated with multivalent display of vi polysaccharide antigen using biodegradable polymer particles. Biomaterials. 33(28), 6843–6857 (2012). https://doi.org/10.1016/j.biomaterials.2012.06.007
doi: 10.1016/j.biomaterials.2012.06.007
pubmed: 22748669
Muthu, S.M., Feng, S.S.: Theranostic liposomes for cancer diagnosis and treatment: current development and pre-clinical success. Expert Opin. Drug Deliv. 10(2), 5 (2013)
doi: 10.1517/17425247.2013.729576
Ingale, S., Wolfert, M.A., Gaekwad, J., Buskas, T., Boons, G.-J.: Robust immune responses elicited by a fully synthetic three-component vaccine. Nat. Chem. Biol. 3(10), 663–667 (2007). https://doi.org/10.1038/nchembio.2007.25
doi: 10.1038/nchembio.2007.25
pubmed: 17767155
pmcid: 2836923
Goyard, D., Shiao, T.C., Fraleigh, N.L., Vu, H.Y., Lee, H., Diaz-Mitoma, F., Le, H.T., Roy, R.: Expedient synthesis of functional single-component glycoliposomes using thiol–yne chemistry. J. Mater. Chem. B. 4(23), 4227–4233 (2016). https://doi.org/10.1039/C6TB00344C
doi: 10.1039/C6TB00344C
pubmed: 32264625
Said Hassane, F., Phalipon, A., Tanguy, M., Guerreiro, C., Bélot, F., Frisch, B., Mulard, L.A., Schuber, F.: Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen. Vaccine. 27(39), 5419–5426 (2009). https://doi.org/10.1016/j.vaccine.2009.06.031
doi: 10.1016/j.vaccine.2009.06.031
pubmed: 19559116
Fernandes, I., Frisch, B., Muller, S., Schuber, F.: Synthetic lipopeptides incorporated in liposomes: in vitro stimulation of the proliferation of murine splenocytes and in vivo induction of an immune response against a peptide antigen. Mol. Immunol. 34(8), 569–576 (1997). https://doi.org/10.1016/S0161-5890(97)00090-4
doi: 10.1016/S0161-5890(97)00090-4
pubmed: 9393959
Price, N.L., Goyette-Desjardins, G., Nothaft, H., Valguarnera, E., Szymanski, C.M., Segura, M., Feldman, M.F.: Glycoengineered outer membrane vesicles: a novel platform for bacterial vaccines. Sci. Rep. 6(1), 24931 (2016). https://doi.org/10.1038/srep24931
doi: 10.1038/srep24931
pubmed: 27103188
pmcid: 4840304
Chen, L., Valentine, J.L., Huang, C. Jr, Endicott, C.E., Moeller, T.D., Rasmussen, J.A., Fletcher, J.R., Boll, J.M., Rosenthal, J.A., Dobruchowska, J., Wang, Z., Heiss, C., Azadi, P., Putnam, D., Trent, M.S., Jones, B.D., DeLisa, M.P.: Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies. Proceedings of the National Academy of Sciences, 201518311 (2016). doi: https://doi.org/10.1073/pnas.1518311113
Holst, J., Oster, P., Arnold, R., Tatley, M., Næss, L., Aaberge, I., Galloway, Y., McNicholas, A., O'Hallahan, J., Rosenqvist, E., Black, S.: Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum. Vaccin. Immunother. 9(6), 1241–1253 (2013). https://doi.org/10.4161/hv.24129
doi: 10.4161/hv.24129
pubmed: 23857274
pmcid: 3901813
Acevedo, R., Fernandez, S., Zayas, C., Acosta, A., Sarmiento, M., Ferro, V., Rosenqvist, E., Campa, C., Cardoso, D., Garcia, L., Perez, J.: Bacterial outer membrane vesicles and vaccine applications. Front. Immunol. 5(121) (2014). doi: https://doi.org/10.3389/fimmu.2014.00121
Gerke, C., Colucci, A.M., Giannelli, C., Sanzone, S., Vitali, C.G., Sollai, L., Rossi, O., Martin, L.B., Auerbach, J., Di Cioccio, V., Saul, A.: Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB. PLoS One 10(8), e0134478 (2015). doi: https://doi.org/10.1371/journal.pone.0134478
Meloni, E., Colucci, A.M., Micoli, F., Sollai, L., Gavini, M., Saul, A., Di Cioccio, V., MacLennan, C.A.: Simplified low-cost production of O-antigen from Salmonella typhimurium generalized modules for membrane antigens (GMMA). J. Biotechnol. 198, 46–52 (2015). https://doi.org/10.1016/j.jbiotec.2015.01.020
Mancini, F., Rossi, O., Necchi, F., Micoli, F.: OMV vaccines and the role of TLR agonists in immune response. Int. J. Mol. Sci. 21(12) (2020). doi: https://doi.org/10.3390/ijms21124416
Walker, M.J., Barnett, T.C., McArthur, J.D., Cole, J.N., Gillen, C.M., Henningham, A., Sriprakash, K.S., Sanderson-Smith, M.L., Nizet, V.: Disease manifestations and pathogenic mechanisms of group a Streptococcus. Clin. Microbiol. Rev. 27(2), 264–301 (2014). https://doi.org/10.1128/CMR.00101-13
doi: 10.1128/CMR.00101-13
pubmed: 24696436
pmcid: 3993104
Carapetis, J.R., Steer, A.C., Mulholland, E.K., Weber, M.: The global burden of group a streptococcal diseases. Lancet Infect. Dis. 5(11), 685–694 (2005). https://doi.org/10.1016/S1473-3099(05)70267-X
doi: 10.1016/S1473-3099(05)70267-X
pubmed: 16253886
Henningham, A., Davies, M.R., Uchiyama, S., van Sorge, N.M., Lund, S., Chen, K.T., Walker, M.J., Cole, J.N., Nizet, V.: Virulence Role of the GlcNAc Side Chain of the Lancefield Cell Wall Carbohydrate Antigen in Non-M1-Serotype Group A <em>Streptococcus</em>. mBio 9(1), e02294–02217 (2018). doi: https://doi.org/10.1128/mBio.02294-17
Salvadori, L.G., Blake, M.S., McCarty, M., Tai, J.Y., Zabriskie, J.B.: Group a Streptococcus-liposome Elisa antibody titers to group a polysaccharide and Opsonophagocytic capabilities of the antibodies. J. Infect. Dis. 171(3), 593–600 (1995). https://doi.org/10.1093/infdis/171.3.593
doi: 10.1093/infdis/171.3.593
pubmed: 7876606
Sabharwal, H., Michon, F., Nelson, D., Dong, W., Fuchs, K., Manjarrez, R.C., Sarkar, A., Uitz, C., Viteri-Jackson, A., Suarez, R.S.R., Blake, M., Zabriskie, J.B.: Group a Streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J. Infect. Dis. 193(1), 129–135 (2006). https://doi.org/10.1086/498618
doi: 10.1086/498618
pubmed: 16323141
Kabanova, A., Margarit, I., Berti, F., Romano, M.R., Grandi, G., Bensi, G., Chiarot, E., Proietti, D., Swennen, E., Cappelletti, E., Fontani, P., Casini, D., Adamo, R., Pinto, V., Skibinski, D., Capo, S., Buffi, G., Gallotta, M., Christ, W.J., Stewart Campbell, A., Pena, J., Seeberger, P.H., Rappuoli, R., Costantino, P.: Evaluation of a group a Streptococcus synthetic oligosaccharide as vaccine candidate. Vaccine. 29(1), 104–114 (2010). https://doi.org/10.1016/j.vaccine.2010.09.018
doi: 10.1016/j.vaccine.2010.09.018
pubmed: 20870056
Auzanneau, F.-I., Borrelli, S., Pinto, B.M.: Synthesis and immunological activity of an oligosaccharide-conjugate as a vaccine candidate against group a Streptococcus. Bioorg. Med. Chem. Lett. 23(22), 6038–6042 (2013). https://doi.org/10.1016/j.bmcl.2013.09.042
doi: 10.1016/j.bmcl.2013.09.042
pubmed: 24103300
Goldstein, I., Rebeyrotte, P., Parlebas, J., Halpern, B.: Isolation from heart valves of Glycopeptides which share immunological properties with Streptococcus haemolyticus group a polysaccharides. Nature. 219(5156), 866–868 (1968). https://doi.org/10.1038/219866a0
doi: 10.1038/219866a0
pubmed: 4970577
Sharma, A.: N.-S.D.: challenges to developing effective streptococcal vaccines to prevent rheumatic fever and rheumatic heart disease. Vaccine: Dev. Ther. 4, 39–54 (2014)
Van Sorge, N.M., Cole, J.N., Kuipers, K., Henningham, A., Aziz, R.K., Kasirer-Friede, A., Lin, L., Berends, E.T.M., Davies, M.R., Dougan, G., Zhang, F., Dahesh, S., Shaw, L., Gin, J., Cunningham, M., Merriman, J.A., Hütter, J., Lepenies, B., Rooijakkers, S.H.M., Malley, R., Walker, M.J., Shattil, S.J., Schlievert, P.M., Choudhury, B., Nizet, V.: The Classical Lancefield Antigen of Group A Streptococcus Is a Virulence Determinant with Implications for Vaccine Design. Cell Host Microbe 15(6), 729–740 (2014). https://doi.org/10.1016/j.chom.2014.05.009
doi: 10.1016/j.chom.2014.05.009
pubmed: 24922575
pmcid: 4078075
Da Silva-Candal, A., Brown, T., Krishnan, V., Lopez-Loureiro, I., Ávila-Gómez, P., Pusuluri, A., Pérez-Díaz, A., Correa-Paz, C., Hervella, P., Castillo, J., Mitragotri, S., Campos, F.: Shape effect in active targeting of nanoparticles to inflamed cerebral endothelium under static and flow conditions. J. Control. Release. 309, 94–105 (2019). https://doi.org/10.1016/j.jconrel.2019.07.026
doi: 10.1016/j.jconrel.2019.07.026
pubmed: 31330214
Furin, J., Cox, H., Pai, M.: Tuberculosis. Lancet. 393(10181), 1642–1656 (2019). https://doi.org/10.1016/S0140-6736(19)30308-3
doi: 10.1016/S0140-6736(19)30308-3
pubmed: 30904262
Dousa, K.M., Kurz, S.G., Bark, C.M., Bonomo, R.A., Furin, J.J.: Drug-resistant tuberculosis: a glance at Progress and global challenges. Infect. Dis. Clin. N. Am. 34(4), 863–886 (2020). https://doi.org/10.1016/j.idc.2020.06.001
doi: 10.1016/j.idc.2020.06.001
Bahuguna, A., Rawat, D.S.: An overview of new antitubercular drugs, drug candidates, and their targets. Med. Res. Rev. 40(1), 263–292 (2020). https://doi.org/10.1002/med.21602
doi: 10.1002/med.21602
pubmed: 31254295
Hamasur, B., Haile, M., Pawlowski, A., Schröder, U., Williams, A., Hatch, G., Hall, G., Marsh, P., Källenius, G., Svenson, S.B.: Mycobacterium tuberculosis arabinomannan–protein conjugates protect against tuberculosis. Vaccine. 21(25), 4081–4093 (2003). https://doi.org/10.1016/S0264-410X(03)00274-3
doi: 10.1016/S0264-410X(03)00274-3
pubmed: 12922145
Kallenius, G., Pawlowski, A., Hamasur, B., Svenson, S.B.: Mycobacterial glycoconjugates as vaccine candidates against tuberculosis. Trends Microbiol. 16(10), 456–462 (2008). https://doi.org/10.1016/j.tim.2008.07.007
doi: 10.1016/j.tim.2008.07.007
pubmed: 18774297
Burygin, G.L., Abronina, P.I., Podvalnyy, N.M., Staroverov, S.A., Kononov, L.O., Dykman, L.A.: Preparation and in vivo evaluation of glyco-gold nanoparticles carrying synthetic mycobacterial hexaarabinofuranoside. Beilstein J. Nanotechnol. 11, 480–493 (2020). https://doi.org/10.3762/bjnano.11.39
doi: 10.3762/bjnano.11.39
pubmed: 32274287
pmcid: 7113550
Girard, M.P., Preziosi, M.-P., Aguado, M.-T., Kieny, M.P.: A review of vaccine research and development: meningococcal disease. Vaccine. 24(22), 4692–4700 (2006). https://doi.org/10.1016/j.vaccine.2006.03.034
doi: 10.1016/j.vaccine.2006.03.034
pubmed: 16621189
Greenwood, B.: Priorities for research on meningococcal disease and the impact of serogroup a vaccination in the African meningitis belt. Vaccine. 31(11), 1453–1457 (2013). https://doi.org/10.1016/j.vaccine.2012.12.035
doi: 10.1016/j.vaccine.2012.12.035
pubmed: 23273967
Baxter, R., Reisinger, K., Block, S.L., Percell, S., Odrljin, T., Dull, P.M., Smolenov, I.: Antibody persistence after primary and booster doses of a Quadrivalent meningococcal conjugate vaccine in adolescents. Pediatr. Infect. Dis. J. 33(11), 1169–1176 (2014). https://doi.org/10.1097/inf.0000000000000438
doi: 10.1097/inf.0000000000000438
pubmed: 24911896
Ubale, R.V., D'Souza, M.J., Infield, D.T., McCarty, N.A., Zughaier, S.M.: Formulation of meningococcal capsular polysaccharide vaccine-loaded microparticles with robust innate immune recognition. J. Microencapsul. 30(1), 28–41 (2013). https://doi.org/10.3109/02652048.2012.692402
doi: 10.3109/02652048.2012.692402
pubmed: 22657751
Ubale, R.V., Gala, R.P., Zughaier, S.M., D’Souza, M.J.: Induction of death receptor CD95 and co-stimulatory molecules CD80 and CD86 by meningococcal capsular polysaccharide-loaded vaccine nanoparticles. AAPS J. 16(5), 986–993 (2014). https://doi.org/10.1208/s12248-014-9635-2
doi: 10.1208/s12248-014-9635-2
pubmed: 24981893
pmcid: 4147039
Gala, R.P., D'Souza, M., Zughaier, S.M.: Evaluation of various adjuvant nanoparticulate formulations for meningococcal capsular polysaccharide-based vaccine. Vaccine. 34(28), 3260–3267 (2016). https://doi.org/10.1016/j.vaccine.2016.05.010
doi: 10.1016/j.vaccine.2016.05.010
pubmed: 27177946
Legnani, L., Ronchi, S., Fallarini, S., Lombardi, G., Campo, F., Panza, L., Lay, L., Poletti, L., Toma, L., Ronchetti, F., Compostella, F.: Synthesis, molecular dynamics simulations, and biology of a carba-analogue of the trisaccharide repeating unit of Streptococcus pneumoniae 19F capsular polysaccharide. Org. Biomol. Chem. 7(21), 4428–4436 (2009). https://doi.org/10.1039/b911323a
doi: 10.1039/b911323a
pubmed: 19830291
Manea, F., Bindoli, C., Fallarini, S., Lombardi, G., Polito, L., Lay, L., Bonomi, R., Mancin, F., Scrimin, P.: Multivalent. Saccharide-Functionalized Gold Nanoparticles as Fully Synthetic Analogs of Type A Neisseria meningitidis Antigens. Advanced Materials. 20(22), 4348–4352 (2008). https://doi.org/10.1002/adma.200800737
doi: 10.1002/adma.200800737
Fallarini, S., Paoletti, T., Battaglini, C.O., Ronchi, P., Lay, L., Bonomi, R., Jha, S., Mancin, F., Scrimin, P., Lombardi, G.: Factors affecting T cell responses induced by fully synthetic glyco-gold-nanoparticles. Nanoscale. 5(1), 390–400 (2013). https://doi.org/10.1039/C2NR32338A
doi: 10.1039/C2NR32338A
pubmed: 23175231
Ramella, D., Polito, L., Mazzini, S., Ronchi, S., Scaglioni, L., Marelli, M., Lay, L.: A Strategy for Multivalent Presentation of Carba Analogues from N. meningitidis A Capsular Polysaccharide. Eur. J. Org. Chem. 2014(27), 5915–5924 (2014). https://doi.org/10.1002/ejoc.201402701
doi: 10.1002/ejoc.201402701
Micoli, F., Alfini, R., Di Benedetto, R., Necchi, F., Schiavo, F., Mancini, F., Carducci, M., Palmieri, E., Balocchi, C., Gasperini, G., Brunelli, B., Costantino, P., Adamo, R., Piccioli, D., Saul, A.: GMMA is a versatile platform to design effective multivalent combination vaccines. Vaccines 8(3), 540 (2020). https://doi.org/10.3390/vaccines8030540
Veesenmeyer, J.L., Hauser, A.R., Lisboa, T., Rello, J.: Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit. Care Med. 37(5), 1777-1786 (2009)
Chatterjee, M., Anju, C.P., Biswas, L., Anil Kumar, V., Gopi Mohan, C., Biswas, R.: Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options. Int. J. Med. Microbiol. 306(1), 48–58 (2016). https://doi.org/10.1016/j.ijmm.2015.11.004
doi: 10.1016/j.ijmm.2015.11.004
pubmed: 26687205
Ciofu, O., Tolker-Nielsen, T.: Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents—how P. aeruginosa can escape antibiotics. Front. Microbiol. 10(913) (2019). doi: https://doi.org/10.3389/fmicb.2019.00913
Shao, X., Xie, Y., Zhang, Y., Liu, J., Ding, Y., Wu, M., Wang, X., Deng, X.: Novel therapeutic strategies for treating Pseudomonas aeruginosa infection. Expert Opin. Drug Discovery. 15(12), 1403–1423 (2020). https://doi.org/10.1080/17460441.2020.1803274
doi: 10.1080/17460441.2020.1803274
Mesaros, N., Nordmann, P., Plésiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., Van Laethem, Y., Jacobs, F., Lebecque, P., Malfroot, A., Tulkens, P.M., Van Bambeke, F.: Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect. 13(6), 560–578 (2007). https://doi.org/10.1111/j.1469-0691.2007.01681.x
Soukarieh, F., Williams, P., Stocks, M.J., Cámara, M.: Pseudomonas aeruginosa quorum sensing systems as drug discovery targets: current position and future perspectives. J. Med. Chem. 61(23), 10385–10402 (2018). https://doi.org/10.1021/acs.jmedchem.8b00540
doi: 10.1021/acs.jmedchem.8b00540
pubmed: 29999316
Bernardi, A., Jiménez-Barbero, J., Casnati, A., De Castro, C., Darbre, T., Fieschi, F., Finne, J., Funken, H., Jaeger, K.-E., Lahmann, M., Lindhorst, T.K., Marradi, M., Messner, P., Molinaro, A., Murphy, P.V., Nativi, C., Oscarson, S., Penadés, S., Peri, F., Pieters, R.J., Renaudet, O., Reymond, J.-L., Richichi, B., Rojo, J., Sansone, F., Schäffer, C., Turnbull, W.B., Velasco-Torrijos, T., Vidal, S., Vincent, S., Wennekes, T., Zuilhof, H., Imberty, A.: Multivalent glycoconjugates as anti-pathogenic agents. Chem. Soc. Rev. 42(11), 4709–4727 (2013). https://doi.org/10.1039/C2CS35408J
doi: 10.1039/C2CS35408J
pubmed: 23254759
Fothergill, J.L., Winstanley, C., James, C.E.: Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. Expert Rev. Anti-Infect. Ther. 10(2), 219–235 (2012). https://doi.org/10.1586/eri.11.168
doi: 10.1586/eri.11.168
pubmed: 22339195
Asadi, A., Razavi, S., Talebi, M., Gholami, M.: A review on anti-adhesion therapies of bacterial diseases. Infection. 47(1), 13–23 (2019). https://doi.org/10.1007/s15010-018-1222-5
doi: 10.1007/s15010-018-1222-5
pubmed: 30276540
Reymond, J.-L., Bergmann, M., Darbre, T.: Glycopeptide dendrimers as Pseudomonas aeruginosa biofilm inhibitors. Chem. Soc. Rev. 42(11), 4814–4822 (2013). https://doi.org/10.1039/C3CS35504G
doi: 10.1039/C3CS35504G
pubmed: 23370573
Michaud, G., Visini, R., Bergmann, M., Salerno, G., Bosco, R., Gillon, E., Richichi, B., Nativi, C., Imberty, A., Stocker, A., Darbre, T., Reymond, J.-L.: Overcoming antibiotic resistance in Pseudomonas aeruginosa biofilms using glycopeptide dendrimers. Chem. Sci. 7(1), 166–182 (2016). https://doi.org/10.1039/C5SC03635F
doi: 10.1039/C5SC03635F
pubmed: 29896342
Baker, S.M., McLachlan, J.B., Morici, L.A.: Immunological considerations in the development of Pseudomonas aeruginosa vaccines. Hum. Vaccin. Immunother. 16(2), 412–418 (2020). https://doi.org/10.1080/21645515.2019.1650999
doi: 10.1080/21645515.2019.1650999
pubmed: 31368828
Priebe, G.P., Goldberg, J.B.: Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev. Vaccines. 13(4), 507–519 (2014). https://doi.org/10.1586/14760584.2014.890053
doi: 10.1586/14760584.2014.890053
pubmed: 24575895
pmcid: 4521563
Pier, G.B.: Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen. Carbohydr. Res. 338(23), 2549–2556 (2003). https://doi.org/10.1016/S0008-6215(03)00312-4
doi: 10.1016/S0008-6215(03)00312-4
pubmed: 14670716
Safari Zanjani, L., Shapoury, R., Dezfulian, M., Mahdavi, M., Shafieeardestani, M.: Protective potential of Conjugated P. aeruginosa LPS –PLGA nanoparticles in mice as a Nanovaccine. Iran. J. Immunol. 17(1), 75–86 (2020). https://doi.org/10.22034/iji.2020.80296
doi: 10.22034/iji.2020.80296
pubmed: 32224543
Jajere, S.M.: A review of Salmonella enterica with particular focus on the pathogenicity and virulence factors, host specificity and antimicrobial resistance including multidrug resistance. Vet World. 12(4), 504–521 (2019). https://doi.org/10.14202/vetworld.2019.504-521
doi: 10.14202/vetworld.2019.504-521
pubmed: 31190705
pmcid: 6515828
Liston, S.D., Ovchinnikova, O.G., Whitfield, C.: Unique lipid anchor attaches Vi antigen capsule to the surface of <em>Salmonella enterica</em> serovar Typhi. Proc. Natl. Acad. Sci. 113(24), 6719 (2016). https://doi.org/10.1073/pnas.1524665113
doi: 10.1073/pnas.1524665113
pubmed: 27226298
pmcid: 4914157
Hu, X., Chen, Z., Xiong, K., Wang, J., Rao, X., Cong, Y.: Vi capsular polysaccharide: synthesis, virulence, and application. Crit. Rev. Microbiol. 43(4), 440–452 (2017). https://doi.org/10.1080/1040841X.2016.1249335
doi: 10.1080/1040841X.2016.1249335
pubmed: 27869515
Radha, S., Murugesan, M., Rupali, P.: Drug resistance in Salmonella Typhi: implications for South Asia and travel. Curr. Opin. Infect. Dis. 33(5) (2020)
da Silva, R.L., da Silva, J.R., Júnior, A.P.D., Marinho, P.S.B., Santos, L.S., Teixeira, F.M., Júnior, J.O.C.S., Costa, R.M.R.: Adsorption of vi capsular antigen of Salmonella Typhi in chitosan-poly (Methacrylic acid) nanoparticles. Polymers (Basel). 11(7), 1226 (2019). https://doi.org/10.3390/polym11071226
doi: 10.3390/polym11071226
Ao, T., Feasey, N., Gordon, M., Keddy, K., Angulo, F., Crump, J.: Global burden of invasive Nontyphoidal <em>Salmonella</em> disease, 2010. Emerg. Infect. Dis. J. 21(6), 941 (2015). https://doi.org/10.3201/eid2106.140999
doi: 10.3201/eid2106.140999
MacLennan, C.A., Martin, L.B., Micoli, F.: Vaccines against invasive Salmonella disease. Hum. Vaccin. Immunother. 10(6), 1478–1493 (2014). https://doi.org/10.4161/hv.29054
doi: 10.4161/hv.29054
pubmed: 24804797
pmcid: 4185946
Micoli, F., Rondini, S., Alfini, R., Lanzilao, L., Necchi, F., Negrea, A., Rossi, O., Brandt, C., Clare, S., Mastroeni, P., Rappuoli, R., Saul, A., MacLennan, C.A.: Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal <em>Salmonella</em>. Proc. Natl. Acad. Sci. 115(41), 10428 (2018). doi: https://doi.org/10.1073/pnas.1807655115
UNICEF, p.r.: One child dies of pneumonia every 39 seconds, agencies warn. https://www.unicef.org/press-releases/one-child-dies-pneumonia-every-39-seconds-agencies-warn (2019)
Geno, K.A., Gilbert, G.L., Song, J.Y., Skovsted, I.C., Klugman, K.P., Jones, C., Konradsen, H.B., Nahm, M.H.: Pneumococcal capsules and their types: past, present, and future. Clin. Microbiol. Rev. 28(3), 871 (2015). https://doi.org/10.1128/CMR.00024-15
doi: 10.1128/CMR.00024-15
pubmed: 26085553
pmcid: 4475641
Klugman, K.P., Dagan, R., Malley, R., Whitney, C.G.: 46 - pneumococcal conjugate vaccine and pneumococcal common protein vaccines. In: Plotkin, S.a., Orenstein, W.a., Offit, P.a., Edwards, K.M. (Eds.) Plotkin's Vaccines (Seventh Edition). Pp. 773–815.e718. Elsevier, (2018)
Platt, H.L., Greenberg, D., Tapiero, B., Clifford, R.A., Klein, N.P., Hurley, D.C., Shekar, T., Li, J., Hurtado, K., Su, S.-C., Nolan, K.M., Acosta, C.J., McFetridge, R.D., Bickham, K., Musey, L.K., For the, V.S.G.: a phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants. Pediatr. Infect. Dis. J. 39(8) (2020)
Ermlich, S.J., Andrews, C.P., Folkerth, S., Rupp, R., Greenberg, D., McFetridge, R.D., Hartzel, J., Marchese, R.D., Stek, J.E., Abeygunawardana, C., Musey, L.K.: Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine 36(6875–6882) (2018)
Stacey, H.L., Rosen, J., Peterson, J.T., Williams-Diaz, A., Gakhar, V., Sterling, T.M., Acosta, C.J., Nolan, K.M., Li, J., Pedley, A., Benner, P., Abeygunawardana, C., Kosinski, M., Smith, W.J., Pujar, H., Musey, L.K.: Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum. Vaccin. Immunother. 15(3), 530–539 (2019). https://doi.org/10.1080/21645515.2018.1532249
doi: 10.1080/21645515.2018.1532249
pubmed: 30648919
pmcid: 6605726
Thompson, A., Lamberth, E., Severs, J., Scully, I., Tarabar, S., Ginis, J., Jansen, K.U., Gruber, W.C., Scott, D.A., Watson, W.: Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 37(42), 6201–6207 (2019). https://doi.org/10.1016/j.vaccine.2019.08.048
doi: 10.1016/j.vaccine.2019.08.048
pubmed: 31495592
Morelli, L., Lay, L.: Synthesis of Neisseria meningitidis X capsular polysaccharide fragments. Arkivoc, 166–184 (2013). doi: https://doi.org/10.3998/ark.5550190.0014.214
Morelli, L., Fallarini, S., Lombardi, G., Colombo, C., Lay, L., Compostella, F.: Synthesis and biological evaluation of a trisaccharide repeating unit derivative of Streptococcus pneumoniae 19A capsular polysaccharide. Bioorg. Med. Chem. 26(21), 5682–5690 (2018). https://doi.org/10.1016/j.bmc.2018.10.016
doi: 10.1016/j.bmc.2018.10.016
pubmed: 30449426
Giuliani, M., Faroldi, F., Morelli, L., Torre, E., Lombardi, G., Fallarini, S., Sansone, F., Compostella, F.: Exploring calixarene-based clusters for efficient functional presentation of Streptococcus pneumoniae saccharides. Bioorg. Chem. 93, 103305 (2019). https://doi.org/10.1016/j.bioorg.2019.103305
doi: 10.1016/j.bioorg.2019.103305
pubmed: 31586712
Oldrini, D., Fiebig, T., Romano, M.R., Proietti, D., Berger, M., Tontini, M., De Ricco, R., Santini, L., Morelli, L., Lay, L.G., Gerardy-Schahn, R., Berti, F., Adamo, R.: Combined chemical synthesis and tailored enzymatic elongation provide fully synthetic and conjugation-ready Neisseria meningitidis serogroup X vaccine antigens. ACS Chem. Biol. 13(4), 984–994 (2018). doi: https://doi.org/10.1021/acschembio.7b01057
Safari, D., Marradi, M., Chiodo, F., Dekker, H.A.T., Shan, Y.L., Adamo, R., Oscarson, S., Rijkers, G.T., Lahmann, M., Kamerling, J.P., Penades, S., Snippe, H.: Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine. Nanomedicine. 7(5), 651–662 (2012). https://doi.org/10.2217/Nnm.11.151
doi: 10.2217/Nnm.11.151
pubmed: 22630149
Vetro, M., Safari, D., Fallarini, S., Salsabila, K., Lahmann, M., Penades, S., Lay, L., Marradi, M., Compostella, F.: Preparation and immunogenicity of gold glyco-nanoparticles as antipneumococcal vaccine model. Nanomedicine. 12(1), 13–23 (2017). https://doi.org/10.2217/nnm-2016-0306
doi: 10.2217/nnm-2016-0306
pubmed: 27879152
Kotloff, K.L., Riddle, M.S., Platts-Mills, J.A., Pavlinac, P., Zaidi, A.K.M.: Shigellosis. The Lancet. 391(10122), 801–812 (2018). https://doi.org/10.1016/S0140-6736(17)33296-8
doi: 10.1016/S0140-6736(17)33296-8
Khalil, I.A., Troeger, C., Blacker, B.F., Rao, P.C., Brown, A., Atherly, D.E., Brewer, T.G., Engmann, C.M., Houpt, E.R., Kang, G., Kotloff, K.L., Levine, M.M., Luby, S.P., MacLennan, C.A., Pan, W.K., Pavlinac, P.B., Platts-Mills, J.A., Qadri, F., Riddle, M.S., Ryan, E.T., Shoultz, D.A., Steele, A.D., Walson, J.L., Sanders, J.W., Mokdad, A.H., Murray, C.J.L., Hay, S.I., Reiner, R.C.: Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990–2016. Lancet Infect. Dis. 18(11), 1229–1240 (2018). https://doi.org/10.1016/S1473-3099(18)30475-4
doi: 10.1016/S1473-3099(18)30475-4
pubmed: 30266330
pmcid: 6202441
Barel, L.-A., Mulard, L.A.: Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human. Hum. Vaccin. Immunother.\. 15(6), 1338–1356 (2019). https://doi.org/10.1080/21645515.2019.1606972
doi: 10.1080/21645515.2019.1606972
pubmed: 31158047
pmcid: 6663142
Perepelov, A.V., Shekht, M.E., Liu, B., Shevelev, S.D., Ledov, V.A., Senchenkova, S.Y.N., L’Vov, V.L., Shashkov, A.S., Feng, L., Aparin, P.G., Wang, L., Knirel, Y.A.: Shigella flexneri O-antigens revisited: final elucidation of the O-acetylation profiles and a survey of the O-antigen structure diversity. FEMS Immunol. Med. Microbiol. 66(2), 201–210 (2012). https://doi.org/10.1111/j.1574-695X.2012.01000.x
doi: 10.1111/j.1574-695X.2012.01000.x
pubmed: 22724405
Pozsgay, V., Chu, C., Pannell, L., Wolfe, J., Robbins, J.B., Schneerson, R.: Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. 96(9), 5194 (1999). https://doi.org/10.1073/pnas.96.9.5194
doi: 10.1073/pnas.96.9.5194
pubmed: 10220442
pmcid: 21840
Phalipon, A., Tanguy, M., Grandjean, C., Guerreiro, C., Bélot, F., Cohen, D., Sansonetti, P.J., Mulard, L.A.: A Synthetic Carbohydrate-Protein Conjugate Vaccine Candidate against <em>Shigella flexneri</em> 2a Infection. J. Immunol. 182(4), 2241 (2009). https://doi.org/10.4049/jimmunol.0803141
doi: 10.4049/jimmunol.0803141
pubmed: 19201878
van der Put, R.M.F., Kim, T.H., Guerreiro, C., Thouron, F., Hoogerhout, P., Sansonetti, P.J., Westdijk, J., Stork, M., Phalipon, A., Mulard, L.A.: A synthetic carbohydrate conjugate vaccine candidate against shigellosis: improved bioconjugation and impact of alum on immunogenicity. Bioconjug. Chem. 27(4), 883–892 (2016). doi: https://doi.org/10.1021/acs.bioconjchem.5b00617
Serapian, S.A., Marchetti, F., Triveri, A., Morra, G., Meli, M., Moroni, E., Sautto, G.A., Rasola, A., Colombo, G.: The answer lies in the energy: how simple atomistic molecular dynamics simulations may hold the key to epitope prediction on the fully glycosylated SARS-CoV-2 spike protein. J. Phys. Chem. Lett. 11(19), 8084–8093 (2020). https://doi.org/10.1021/acs.jpclett.0c02341
doi: 10.1021/acs.jpclett.0c02341
pubmed: 32885971
pmcid: 7491317
Lee, C.-R., Lee, J.H., Park, M., Park, K.S., Bae, I.K., Kim, Y.B., Cha, C.-J., Jeong, B.C., Lee, S.H.: Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front. Cell. Infect. Microbiol. 7(55) (2017). doi: https://doi.org/10.3389/fcimb.2017.00055
Russo, T.A., Beanan, J.M., Olson, R., MacDonald, U., Cox, A.D., St. Michael, F., Vinogradov, E.V., Spellberg, B., Luke-Marshall, N.R., Campagnari, A.A.: The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect. Immun. 81(3), 915 (2013). https://doi.org/10.1128/IAI.01184-12
doi: 10.1128/IAI.01184-12
pubmed: 23297385
pmcid: 3584894
Singh, J.K., Adams, F.G., Brown, M.H.: Diversity and function of capsular polysaccharide in Acinetobacter baumannii. Front. Microbiol. 9(3301) (2019). doi: https://doi.org/10.3389/fmicb.2018.03301